HUP0100044A1 - A humán Ha-ras gén egy szakaszával komplementer, módosított antiszensz oligonukleotidok - Google Patents

A humán Ha-ras gén egy szakaszával komplementer, módosított antiszensz oligonukleotidok

Info

Publication number
HUP0100044A1
HUP0100044A1 HU0100044A HUP0100044A HUP0100044A1 HU P0100044 A1 HUP0100044 A1 HU P0100044A1 HU 0100044 A HU0100044 A HU 0100044A HU P0100044 A HUP0100044 A HU P0100044A HU P0100044 A1 HUP0100044 A1 HU P0100044A1
Authority
HU
Hungary
Prior art keywords
human
section
ras gene
nucleotides complementary
modified antisense
Prior art date
Application number
HU0100044A
Other languages
English (en)
Inventor
Esther Chang
Anuschirwan Peyman
Kathleen Pirollo
Antonina Rait
Eugen Uhlmann
David William Will
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of HUP0100044A1 publication Critical patent/HUP0100044A1/hu
Publication of HUP0100044A3 publication Critical patent/HUP0100044A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya olyan specifikus, módosítottoligonukleotid, amely komplementer a human Ha-ras gén és mRNS egyszakaszával. Szintén a találmány tárgyát képezi az ilyenoligonukleotid alkalmazása a Ha-ras gén expressziójának specifikusszabályozására, módosítására, illetve gátlására; a találmány szerintioligonukleotid alkalmazása a Ha-ras gén rendellenes expressziójábóleredő állapotok kezelésére alkalmas gyógyszer előállítására; atalálmány szerinti oligonukleotidot tartalmazó gyógyászati készítmény;valamint eljárás a találmány szerinti oligonukleotid előállítására. Ó
HU0100044A 1997-05-05 1998-04-30 Modified antisense nucleotides complementary to a section of the human ha-ras gene HUP0100044A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97107404 1997-05-05
PCT/EP1998/002546 WO1998050540A1 (en) 1997-05-05 1998-04-30 MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE

Publications (2)

Publication Number Publication Date
HUP0100044A1 true HUP0100044A1 (hu) 2001-05-28
HUP0100044A3 HUP0100044A3 (en) 2003-08-28

Family

ID=8226765

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100044A HUP0100044A3 (en) 1997-05-05 1998-04-30 Modified antisense nucleotides complementary to a section of the human ha-ras gene

Country Status (10)

Country Link
US (2) US6723706B2 (hu)
EP (1) EP0979273A1 (hu)
JP (1) JP2002501505A (hu)
KR (1) KR100518108B1 (hu)
CN (1) CN1304572C (hu)
AU (1) AU744417B2 (hu)
BR (1) BR9809242A (hu)
CA (1) CA2288946A1 (hu)
HU (1) HUP0100044A3 (hu)
WO (1) WO1998050540A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368855B1 (en) * 1996-06-11 2002-04-09 Antigen Express, Inc. MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20090099117A1 (en) * 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
WO2005099363A2 (en) 2004-03-26 2005-10-27 Whitehead Institute For Biomedical Research Methods of diagnosing, preventing and treating cancer metastasis
JP5107047B2 (ja) 2004-11-09 2012-12-26 サンタリス ファーマ アー／エス Ｌｎａオリゴヌクレオチドおよび癌の処置
PT2511301T (pt) 2006-08-04 2018-03-08 Medimmune Ltd Anticorpos humanos para erbb2
US8569252B2 (en) * 2009-04-15 2013-10-29 Postech Academy-Industry Foundation Nucleolin specific aptamer and use thereof
SG10201804331TA (en) 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5582986A (en) 1991-06-14 1996-12-10 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
CA2111472A1 (en) 1991-06-14 1992-12-23 Brett P. Monia Antisense oligonucleotide inhibition of the ras gene
NZ245720A (en) 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe
JPH08506087A (ja) * 1992-10-21 1996-07-02 テンプル ユニバーシティ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ガン処置のための抗腫瘍薬とアンチセンスオリゴヌクレオチドの組み合わせ
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives

Also Published As

Publication number Publication date
CA2288946A1 (en) 1998-11-12
KR100518108B1 (ko) 2005-10-04
AU744417B2 (en) 2002-02-21
CN1304572C (zh) 2007-03-14
WO1998050540A1 (en) 1998-11-12
HUP0100044A3 (en) 2003-08-28
CN1255164A (zh) 2000-05-31
AU7760298A (en) 1998-11-27
US20030064514A1 (en) 2003-04-03
US6723706B2 (en) 2004-04-20
KR20010012238A (ko) 2001-02-15
BR9809242A (pt) 2000-06-27
JP2002501505A (ja) 2002-01-15
US20050020523A1 (en) 2005-01-27
EP0979273A1 (en) 2000-02-16

Similar Documents

Publication Publication Date Title
HUP0002296A2 (hu) Sertralinsók és a sertralin elnyújtott felszabadulását biztosító dózisformák
HUP9802445A2 (hu) Liposzómás oligonukleotid készítmények és eljárás human RAF kifejeződésének gátlására
MY125821A (en) Pharmaceutical composition of topiramate
HUP9900172A2 (hu) Idegrendszeri elváltozások kezelésére alkalmas 10-aciloxi-10,11-dihidrobenz/b,f/azepin-5-karboxamid, előállítása és ezt tartalmazó gyógyszerkészítmény
IS5198A (is) Ný efnasambönd
AU3368497A (en) Human dnase i hyperactive variants
EP1390472A4 (en) NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
HUP0103376A2 (hu) Új 3-aril-2-hidroxi-propinsav-származék, ezt tartalmazó gyógyszerkészítmények, eljárás az előállításukra és alkalmazásuk
WO1996019568A3 (en) Stabilized ribozyme analogs
HUP9902105A2 (hu) Angiosztatikus dipeptideket tartalmazó gyógyászati készítmények és ezek alkalmazása
HU9503545D0 (en) Novel chemical compounds having pde-iv inhibition activity
ATE234919T1 (de) Antisense nukleinsäuren zur vorbeugung und behandlung von beschwerden in welchen die exprimierung von c-erbb-2 eine rolle spielt
EP0831848A4 (en) METHOD FOR TREATING LUNG DISEASES WITH ANTISENSE OLIGONUCLEOTIDES
HUP0202794A2 (en) Oligonucleotides for inhibiting the expression of human eg5
HUP0100044A1 (hu) A humán Ha-ras gén egy szakaszával komplementer, módosított antiszensz oligonukleotidok
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
HUP0001014A2 (hu) Gasztrointesztinális lipáz inhibitorok felhasználása
HUP9900819A1 (hu) Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában
EP0775745A3 (en) Cathepsin G-inhibiting aptamers
HUP0103206A2 (hu) Merevedési zavarok kezelésére szolgáló eszköz és eljárás az előállítására
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
HUP9904294A2 (hu) Topiramát származékok alkalmazása neuropátiás fájdalom kezelésére alkalmas gyógyszer előállítására
EP0744176A3 (en) Methods for inhibiting bone loss
ATE242200T1 (de) Valnoctamid-stereoisomere, eine methode zu ihrer herstellung und abtrennung und ihre anwendungen

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees